Analytical Data
-
Gene name
EP1
- Application
-
Alternative Names
EP1；Prostaglandin E2 receptor EP1 subtype
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P34995
-
Expression Region
1-402aa
-
AA Sequence
MSPCGPLNLSLAGEATTCAAPWVPNTSAVPPSGASPALPIFSMTLGAVSNLLALALLAQAAGRLRRRRSAATFLLFVASLLATDLAGHVIPGALVLRLYTAGRAPAGGACHFLGGCMVFFGLCPLLLGCGMAVERCVGVTRPLLHAARVSVARARLALAAVAAVALAVALLPLARVGRYELQYPGTWCFIGLGPPGGWRQALLAGLFASLGLVALLAALVCNTLSGLALLRARWRRRSRRPPPASGPDSRRRWGAHGPRSASASSASSIASASTFFGGSRSSGSARRARAHDVEMVGQLVGIMVVSCICWSPMLVLVALAVGGWSSTSLQRPLFLAVRLASWNQILDPWVYILLRQAVLRQLLRLLPPRAGAKGGPAGLGLTPSAWEASSLRSSRHSGLSHF
-
Molecular Weight
41.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EP1 recombinant protein research has gained significant attention in recent years due to its potential applications in both basic science and biotechnology. EP1, a fusion protein derived from various biological sources, is recognized for its ability to elicit robust immune responses, making it a candidate for vaccine development and therapeutic interventions against infectious diseases. The increasing prevalence of various pathogens necessitates the exploration of novel approaches to combat these threats, and recombinant proteins offer a promising avenue for developing targeted therapies. Advances in genetic engineering and expression systems have enabled the efficient production of EP1, allowing researchers to investigate its structural properties, functional mechanisms, and interactions with host immune cells. Furthermore, understanding the biochemical pathways influenced by EP1 can provide insights into immune modulation, paving the way for innovative treatments for autoimmune disorders and allergies. As a result, ongoing studies focus on optimizing the expression and purification processes of EP1, as well as evaluating its safety and efficacy in preclinical models. This research is crucial for establishing EP1 as a viable candidate for clinical applications, thereby contributing to global health initiatives aimed at enhancing disease prevention and treatment strategies.
